Potential OPDIVO® (nivolumab) user taking a selfie with his son.

Discover an immunotherapy cancer treatment that may be faster*

OPDIVO Qvantig™ is an FDA-approved alternative for most types of solid tumor cancer in adults that can be treated with OPDIVO® (nivolumab).

Explore this injectable option

Actor portrayals.

*A 3-5 minute injection time of OPDIVO Qvantig compared to 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab).

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

Explore another way you may receive treatment

You and your healthcare provider may have a choice between under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig and intravenous (lV) infusions with OPDIVO

Hands perusing OPDIVO® (nivolumab) patient resources.

Helpful patient resources

Explore resources to help you along your treatment journey

Frequently asked questions about treatment with OPDIVO® (nivolumab).

Have questions about treatment?

We have answers about getting treatment, monitoring, and more

Hands exploring cost information and financial help for OPDIVO® (nivolumab).

Cost information and financial help

Find information about cost and access to OPDIVO

OPDIVO and OPDIVO Qvantig will not work for everyone. Individual results may vary.